MaaT Pharma, a French clinical-stage biotech (Phase 3) and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, and Skyepharma, a contract development and manufacturing organization (CDMO) specialized in formulating and manufacturing complex and controlled release drugs, have entered a partnership agreement to build, to date, France’s largest specialized cGMP manufacturing facility for ecosystem microbiome-based t...